Norges Bank’s Ovid Therapeutics OVID Stock Holding History

Norges Bank’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-12,155	Closed	-$128K	–	2142
2017 Q2	$128K	Buy	+12,155	New	+$159K	﹤0.01%	2114

Other funds holding OVID

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Norges Bank's OVID Position: Q3 2017 in Review

Norges Bank sold out of Ovid Therapeutics (OVID) in Q3 2017, closing a stake of 12,155 shares — an estimated $128K sold.

Norges Bank first reported a position in OVID in Q2 2017 and held it in 1 quarter. The position peaked at $128K in Q2 2017. 42 funds tracked by Wall St. Rank hold OVID as of Q3 2017.

Norges Bank reported no remaining Ovid Therapeutics position as of Q3 2017 after selling out during the quarter.
Norges Bank sold 12,155 Ovid Therapeutics shares in Q3 2017, an estimated $128K.
Norges Bank first reported a position in Ovid Therapeutics in Q2 2017 and held it in 1 quarter.
Norges Bank's Ovid Therapeutics position peaked at $128K in Q2 2017.
42 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2017.

Based on Norges Bank's 13F filing for Q3 2017, filed 7 Nov 2017.